Chow Selina, Ding Keyue, Wan Bo Angela, Brundage Michael, Meyer Ralph M, Nabid Abdenour, Chabot Pierre, Coulombe Genevievev, Ahmed Shahida, Kuk Joda, Dar A Rashid, Mahmud Aamer, Fairchild Alysa, Wilson Carolyn F, Wu Jackson S Y, Dennis Kristopher, DeAngelis Carlo, Wong Rebecca K S, Zhu Liting, Chow Edward
Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada.
Canadian Cancer Trials Group, Cancer Research Institute, Queen's University, Kingston, ON, Canada.
Ann Palliat Med. 2017 Dec;6(Suppl 2):S185-S194. doi: 10.21037/apm.2017.08.12. Epub 2017 Aug 29.
Gender differences may contribute to variations in disease presentations and health outcomes. To explore the gender difference in pain and patient reported outcomes in cancer patients with bone metastases undergoing palliative radiotherapy on the National Cancer Institute of Canada (NCIC) SC.23 randomized trial.
Patients completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) bone metastases module (QLQ-BM22) and EORTC QOL Core-15-Palliative (QLQ-C15-PAL) before treatment and at days 10 and 42 after a single 8 Gy radiation treatment. Patient demographics, performance status, analgesic consumption, BM22 and C15 were compared between males and females using the 2-sample t-test for continuous variables or the Chi-squared test for categorical variables. Multiple linear regression models were used to check the difference between gender groups adjusting for the baseline demographics and primary disease sites.
There were 298 patients (170 male, 128 female) with median age of 69 years. The most common primary cancer sites were lung, prostate and breast. At baseline, there were no differences in BM22 and C15 scores, except a worse nausea and vomiting score (P=0.03) in females on the C15. In patients with moderate baseline worst pain scores (WPS), females reported worse scores in painful sites of BM22. At day 42, there was no significant difference in response to radiotherapy. Among the responders, females reported better improvement in emotional aspect.
In cancer patients with bone metastases undergoing palliative radiotherapy, the majority of symptom presentations, patient reported outcomes, and response to radiation was not significantly different between genders.
NCT01248585.
性别差异可能导致疾病表现和健康结果的差异。在加拿大国家癌症研究所（NCIC）SC.23随机试验中，探讨接受姑息性放疗的骨转移癌患者在疼痛及患者报告结局方面的性别差异。
患者在治疗前以及单次8 Gy放射治疗后的第10天和第42天，完成欧洲癌症研究与治疗组织（EORTC）生活质量（QOL）骨转移模块（QLQ - BM22）和EORTC QOL核心-15-姑息治疗模块（QLQ - C15 - PAL）。使用两样本t检验比较男性和女性之间的患者人口统计学、体能状态、镇痛药使用情况、BM22和C15，连续变量采用两样本t检验，分类变量采用卡方检验。使用多元线性回归模型，在调整基线人口统计学和原发疾病部位后，检查性别组之间的差异。
共有298例患者（170例男性，128例女性），中位年龄为69岁。最常见的原发癌部位是肺、前列腺和乳腺。在基线时，BM22和C15评分没有差异，但在C15上女性的恶心和呕吐评分更差（P = 0.03）。在基线最差疼痛评分（WPS）为中度的患者中，女性在BM22的疼痛部位报告的评分更差。在第42天，放疗反应没有显著差异。在有反应的患者中,女性在情绪方面报告有更好的改善。
在接受姑息性放疗的骨转移癌患者中，大多数症状表现、患者报告结局以及对放疗的反应在性别之间没有显著差异。
NCT01248585。
Zotero 插件